Liang Bing, Chen Junhui, Li Tao, Wu Haiying, Yang Wenjie, Li Yanjiao, Li Jianchun, Yu Congtao, Nie Fangang, Ma Zhaoxia, Yang Mingxi, Xiao Mingying, Nie Panrong, Gao Yanfeng, Qian Chuanyun, Hu Min
Department of Critical Care Medicine, Baoshan People's Hospital, Baoshan.
Intervention and Cell Therapy Center, Peking University Shenzhen Hospital, Shenzhen.
Medicine (Baltimore). 2020 Jul 31;99(31):e21429. doi: 10.1097/MD.0000000000021429.
The COVID-19 cases increased very fast in January and February 2020. The mortality among critically ill patients, especially the elder ones, is relatively high. Considering many patients died of severe inflammation response, it is urgent to develop effective therapeutic strategies for these patients. The human umbilical cord mesenchymal stem cells (hUCMSCs) have shown good capabilities to modulate the immune response and repair the injured tissue. Therefore, investigating the potential of hUCMSCs to the treatment of COVID-19 critically ill patients is necessary.
A 65-year-old woman felt fatigued and had a fever with body temperature of 38.2C, coughed up white foaming sputum. After 1 day, she had chest tightness with SPO2 of 81%, and blood pressure of 160/91 mm Hg.
According to the guideline for the diagnosis and treatment of 2019 novel coronavirus infected pneumonia (Trial 4th Edition), COVID-19 was diagnosed, based on the real-time RT-PCR test of SARS-CoV-2.
After regular treatment for 12 days, the inflammation symptom of the patient was still very severe and the potential side effects of corticosteroid were observed. Then, allogenic hUCMSCs were given 3 times (5 × 10 cells each time) with a 3-day interval, together with thymosin α1 and antibiotics daily injection.
After these treatments, most of the laboratory indexes and CT images showed remission of the inflammation symptom. The patient was subsequently transferred out of ICU, and the throat swabs test reported negative 4 days later.
These results indicated the clinical outcome and good tolerance of allogenic hUCMSCs transfer.
2020年1月和2月，新型冠状病毒肺炎（COVID-19）病例增长迅速。危重症患者，尤其是老年患者的死亡率相对较高。鉴于许多患者死于严重的炎症反应，为这些患者制定有效的治疗策略迫在眉睫。人脐带间充质干细胞（hUCMSCs）已显示出良好的调节免疫反应和修复受损组织的能力。因此，研究hUCMSCs治疗COVID-19危重症患者的潜力很有必要。
一名65岁女性感到疲劳，发热，体温38.2℃，咳出白色泡沫痰。1天后，她出现胸闷，血氧饱和度为81%，血压为160/91 mmHg。
根据《新型冠状病毒感染的肺炎诊疗方案（试行第四版）》，基于实时逆转录聚合酶链反应（RT-PCR）检测严重急性呼吸综合征冠状病毒2（SARS-CoV-2），确诊为COVID-19。
常规治疗12天后，患者的炎症症状仍然非常严重，且观察到了皮质类固醇的潜在副作用。随后，每隔3天给予异体hUCMSCs 3次（每次5×10个细胞），同时每天注射胸腺肽α1和抗生素。
经过这些治疗后，大多数实验室指标和胸部CT图像显示炎症症状缓解。患者随后转出重症监护病房（ICU），4天后咽拭子检测报告为阴性。
这些结果表明异体hUCMSCs移植具有良好的临床疗效和耐受性。
